Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.23.1
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 15 Months Ended 27 Months Ended
Jul. 01, 2021
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2022
Dec. 31, 2024
Disaggregation of Revenue [Line Items]              
Total revenue     $ 475   $ 1,173    
Proceeds from short-term debt     400        
Forecast              
Disaggregation of Revenue [Line Items]              
Proceeds from short-term debt   $ 200          
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio              
Disaggregation of Revenue [Line Items]              
Proceeds from divestiture of businesses           $ 2,000  
Total receivable balance     1,400        
Amount fully reserved       $ 1,000      
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio | Forecast              
Disaggregation of Revenue [Line Items]              
Proceeds from divestiture of businesses             $ 1,000
Product revenue, net              
Disaggregation of Revenue [Line Items]              
Total revenue     $ 475   $ 1,173    
Millipred | Teva              
Disaggregation of Revenue [Line Items]              
Percent of net profit for installment payments           50.00%  
Installment payment $ 500            
Major Customer Number One | Sales Revenue | Customer Concentration Risk              
Disaggregation of Revenue [Line Items]              
Concentration risk percentage     53.00%        
Major Customer Number Two | Sales Revenue | Customer Concentration Risk              
Disaggregation of Revenue [Line Items]              
Concentration risk percentage     47.00%